NBE-Therapeutics closes USD 22M Series C financing round
NBE-Therapeutics AG closed a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders. The funds will enable NBE to...
Oviva raises USD 21M to roll out digital diabetes treatment in Europe
Oviva raises USD 21M to roll out digital diabetes treatment in Europe.
The round was led by Swiss healthtech investor MTIP, joined by Earlybird as new investors. Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures...
Resistell Closes Series A Financing Round
Resistell AG has closed a milestone-based CHF 3.5M Series A Financing round led by OCCIDENT. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also back the start-up developing world’s...
Dubai's DP World and Swissterminal enter strategic partnership
DP World and Swissterminal, the leading container terminal operator in Switzerland, have entered a strategic partnership. DP World will take a stake of 44% in Swissterminal Holding AG with the Mayer family, the business' founder,...
AFINUM acquires majority stake in Swiss Interconnect Group
AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG has acquired a majority stake in the Swiss Interconnect Group with headquarters in the canton of Valais, Switzerland. The Swiss Interconnect Group is a leading provider of high...
IMCD Switzerland acquires DCS Pharma
IMCD N.V., a Dutch leading distributor of specialty chemicals and food ingredients acquired Swiss based pharmaceutical distributor DCS Pharma AG through its Swiss subsidiary IMCD Switzerland AG. The staggered acquisition structure...
Numab and Sunshine Guojian form partnership
3SBio Inc.’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific...
ARTIDIS announces CHF 8.8M seed financing round
ARTIDIS AG ("ARTIDIS"), a privately held healthtech company, announced the successful closure of a CHF 8.8M seed financing in two rounds, securing early clinical validation and the next development phase towards market entry in...
Kuros Biosciences AG completes rights offering and share placement
Kuros Biosciences (SIX: KURN) completes a rights offering and share placement in which a total of 6,405,022 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00...
ImmunOs Therapeutics AG raises CHF 15M in Series A Financing
ImmunOs Therapeutics AG, a Swiss biotechnology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million....